retatrutide triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology GLP-3 Retatrutide

Its glucagon receptor affinity is tuned specifically to engage hepatic GCGR without producing a counter-regulatory hyperglycemic signal that would negate the GLP-1 and GIP contributions

GLP-1 receptor agonists mimic the GLP-1 hormone that is naturally released in the gastrointestinal tract in response to eating

Avoid the same foods you avoided on medication since the reasons for avoiding them, rapid glucose spikes, low satiety, gastrointestinal distress, remain relevant even without the medication

Anyone with diabetes, kidney disease, heart disease, digestive problems, pregnancy, or multiple medicines should avoid self-medication and speak to a doctor first

Potential Benefits of Using GLP-1 Supplements

Fatigue is another commonly reported experience, particularly during the first weeks of treatment or after dose increases